D-beta-hydroxybutyrate protects against corneal epithelial disorders in a rat dry eye model with jogging board.
OBJECTIVE
The purpose of this study was to establish a rat dry eye model of corneal epithelial disorders by inducing improper tear dynamics and change in blink frequency. The protective effect of d-beta-hydroxybutyrate (HBA) on the corneal epithelia was also investigated.


METHODS
A series of treatments were performed under continuous exposure to low-humidity airflow. Rats were placed on a jogging board (JB) made of a plastic pipe for 7.5 h/d, and, for 16.5 hours, they were placed in individual cages without JB treatment. The resultant changes in tear dynamics and corneal epithelial structure were then analyzed. Five days after the rats were exposed to the treatment, eyes that showed corneal fluorescein staining were examined, to investigate the effect of HBA, by administration of eye drops containing 80 mM HBA four times daily during JB treatment for 5 days.


RESULTS
Significant reductions in blink frequency, Schirmer score, and tear clearance were recorded during JB treatment in eyes that showed persistent punctate staining of almost one half of the corneal surface. The application of HBA-containing eye drops significantly reduced the punctate staining compared with the initial or phosphate-buffered saline-treated eyes.


CONCLUSIONS
This rat dry eye model, established by repeated JB treatment in desiccating conditions, induced abnormal tear dynamics and superficial punctate keratopathy similar to that in humans. These findings suggest the potential clinical application of HBA in corneal surface epithelial disorders in patients with moderate to mild dry eye.
Nakamura
Shigeru
S
Ophtecs Corporation, Hyogo, Japan. research3@ophtecs.co.jp
Shibuya
Michiko
M
Nakashima
Hideo
H
Imagawa
Tomohiro
T
Uehara
Masato
M
Tsubota
Kazuo
K
D020155:3-Hydroxybutyric Acid / Q000494:pharmacology*; D000818:Animals; D001767:Blinking; D003316:Corneal Diseases / Q000209:etiology / Q000517:prevention & control*; D004195:Disease Models, Animal; D015352:Dry Eye Syndromes / Q000209:etiology / Q000517:prevention & control*; D019573:Epithelium, Corneal / Q000187:drug effects*; D005260:Female; D007766:Lacrimal Apparatus Diseases / Q000150:complications; D009883:Ophthalmic Solutions / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013666:Tears / Q000378:metabolism
D009883:Ophthalmic Solutions; D020155:3-Hydroxybutyric Acid